

Elena Rodriguez-Vieitez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5573279/publications.pdf>

Version: 2024-02-01

38
papers

1,826
citations

586496

16
h-index

563245

28
g-index

42
all docs

42
docs citations

42
times ranked

2973
citing authors

#	ARTICLE	IF	CITATIONS
1	Age, sex and APOE- ϵ 4 modify the balance between soluble and fibrillar β -amyloid in non-demented individuals: topographical patterns across two independent cohorts. <i>Molecular Psychiatry</i> , 2022, 27, 2010-2018.	4.1	9
2	Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid- β positivity. <i>Molecular Psychiatry</i> , 2021, 26, 5864-5874.	4.1	22
3	Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 612-622.	3.3	16
4	Altered perivascular fibroblast activity precedes ALS disease onset. <i>Nature Medicine</i> , 2021, 27, 640-646.	15.2	69
5	Astrocyte Biomarkers in Alzheimer Disease. <i>Neurology</i> , 2021, 96, .	1.5	70
6	Association of cortical microstructure with amyloid- β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. <i>Molecular Psychiatry</i> , 2021, 26, 7813-7822.	4.1	17
7	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 103-117.	1.2	4
8	PET Imaging of Monoamine Oxidase B. , 2021, , 521-545.		4
9	Plasma sTREM2: a potential marker of cerebrovascular injury in neurodegenerative disorders. <i>Brain</i> , 2021, 144, 3283-3285.	3.7	5
10	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
11	The relationship between cortical microstructural changes and in vivo amyloid- β and tau in aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041626.	0.4	0
12	Towards harmonizing subtyping methods for PET and MRI studies of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042807.	0.4	2
13	Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. <i>Brain Communications</i> , 2020, 2, fcaa192.	1.5	24
14	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020, 94, e2026-e2036.	1.5	42
15	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2831-2847.	3.3	45
16	Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes. <i>Neurobiology of Aging</i> , 2019, 82, 40-47.	1.5	7
17	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1369-1382.	3.3	74
18	S20102: PET MARKERS OF ASTROCYTES. <i>Alzheimer's and Dementia</i> , 2019, 15, P514.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Tau PET imaging in neurodegenerative tauopathiesâ€”still a challenge. <i>Molecular Psychiatry</i> , 2019, 24, 1112-1134.	4.1	409
20	Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimerâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 348-356.	3.3	41
21	Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 232-236.	1.2	86
22	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. , 2018, 14, 652-663.		18
23	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 45.	3.0	11
24	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. <i>Methods in Molecular Biology</i> , 2018, 1750, 231-251.	0.4	18
25	Comparability of [¹⁸ F]THK5317 and [¹¹ C]PIB blood flow proxy images with [¹⁸ F]FDG positron emission tomography in Alzheimerâ€™s disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 740-749.	2.4	46
26	Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimerâ€™s Disease. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 195-203.	1.2	18
27	Tau PET imaging: present and future directions. <i>Molecular Neurodegeneration</i> , 2017, 12, 19.	4.4	220
28	[P4â€“533]: GENOTYPE-DEPENDENT LONGITUDINAL TRAJECTORIES OF COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1554.	0.4	0
29	P4â€“349: EARLY-PHASE [11C]PIB PET is Comparable to [18F]FDG PET as a Marker of Disease Progression in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P1171.	0.4	0
30	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimerâ€™s disease. <i>Brain</i> , 2016, 139, 922-936.	3.7	235
31	Comparison of Early-Phase ¹¹ C-Deuterium-l-Deprenyl and ¹¹ C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1071-1077.	2.8	63
32	IC-P-126: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P86-P86.		0
33	O1-02-03: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P127-P127.		0
34	Early astrocytosis in autosomal dominant Alzheimerâ€™s disease measured in vivo by multi-tracer positron emission tomography. <i>Scientific Reports</i> , 2015, 5, 16404.	1.6	110
35	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 661-667.	1.2	14
36	Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1119-1132.	3.3	121

#	ARTICLE	IF	CITATIONS
37	IC-03-03: COMPARISON OF MEASUREMENTS OF CEREBRAL BLOOD FLOW BY EARLY FRAMES OF 11C-DEUTERIUM-L-DEPRENYL (11C-DED) AND 11C-PIB PET TRACERS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE. , 2014, 10, P7-P7.		1
38	P3-214: COMPARISON OF MEASUREMENTS OF CEREBRAL BLOOD FLOW BY EARLY FRAMES OF 11C-DEUTERIUM-L-DEPRENYL (11C-DED) AND 11C-PIB PET TRACERS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE. , 2014, 10, P709-P709.		0